Vivek Subbiah
Impact in
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways
- Lung Cancer Research Studies
- Cancer Research top 0.2%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 261
- Cancer Immunotherapy and Biomarkers 68
- Colorectal Cancer Treatments and Studies 52
- CAR-T cell therapy research 37
- Pancreatic and Hepatic Oncology Research 29
-
- Lung Cancer Treatments and Mutations 122
- Sarcoma Diagnosis and Treatment 59
- Co-authors
- Razelle Kurzrock (78 shared papers)Funda Meric‐Bernstam (138 shared papers)David S. Hong (159 shared papers)Filip Jankú (119 shared papers)Aung Naing (111 shared papers)Siqing Fu (110 shared papers)Maria E. Cabanillas (28 shared papers)Sarina A. Piha‐Paul (122 shared papers)
- Journals
- Journal of Clinical Oncology (164 papers)Annals of Oncology (37 papers)Cancer Research (36 papers)Clinical Cancer Research (22 papers)JCO Precision Oncology (20 papers)
- Partner nations
- United StatesFranceSpain
In The Last Decade
Vivek Subbiah
570 papers receiving 12.9k citations
Vivek Subbiah's Hit Papers
Peers
Comparison fields: 5 of 152
- Oncology 5.2k
- Cancer Research 2.7k
- Pulmonary and Respiratory Medicine 4.1k
- Endocrinology, Diabetes and Metabolism 1.3k
- Pathology and Forensic Medicine 1.4k
Countries citing papers authored by Vivek Subbiah
This map shows the geographic impact of Vivek Subbiah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vivek Subbiah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vivek Subbiah more than expected).
Fields of papers citing papers by Vivek Subbiah
This network shows the impact of papers produced by Vivek Subbiah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vivek Subbiah. The network helps show where Vivek Subbiah may publish in the future.
Co-authors
The 25 scholars most cited alongside Vivek Subbiah, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 606 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer Hit paper breakdown → | 2017 | 635 |
| 2 | Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial Hit paper breakdown → | 2020 | 332 |
| 3 | The next generation of evidence-based medicine Hit paper breakdown → | 2023 | 305 |
| 4 | Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial Hit paper breakdown → | 2022 | 262 |
| 5 | 2016 | 256 | |
| 6 | 2020 | 233 | |
| 7 | Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers Hit paper breakdown → | 2021 | 214 |
| 8 | 2016 | 210 | |
| 9 | Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study Hit paper breakdown → | 2022 | 200 |
| 10 | 2020 | 185 | |
| 11 | 2020 | 170 | |
| 12 | 2016 | 160 | |
| 13 | 2016 | 156 | |
| 14 | Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial Hit paper breakdown → | 2022 | 155 |
| 15 | 2021 | 141 | |
| 16 | 2022 | 134 | |
| 17 | Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial Hit paper breakdown → | 2022 | 132 |
| 18 | 2009 | 132 | |
| 19 | 2009 | 124 | |
| 20 | 2017 | 115 |
About Vivek Subbiah
Vivek Subbiah is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 606 papers that have together received 13.1k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (135 papers), Lung Cancer Treatments and Mutations (122 papers), Cancer Immunotherapy and Biomarkers (68 papers), Sarcoma Diagnosis and Treatment (59 papers), Colorectal Cancer Treatments and Studies (52 papers), Melanoma and MAPK Pathways (37 papers), CAR-T cell therapy research (37 papers) and Pancreatic and Hepatic Oncology Research (29 papers). The work is most often cited by research in Oncology (5.2k citations), Cancer Research (2.7k citations), Pulmonary and Respiratory Medicine (4.1k citations), Endocrinology, Diabetes and Metabolism (1.3k citations) and Pathology and Forensic Medicine (1.4k citations). Vivek Subbiah has collaborated with scholars based in United States, France and Spain. Frequent co-authors include Razelle Kurzrock, Funda Meric‐Bernstam, David S. Hong, Filip Jankú, Aung Naing, Siqing Fu, Maria E. Cabanillas, Sarina A. Piha‐Paul, Apostolia M. Tsimberidou and Mohamed A. Gouda. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Clinical Cancer Research and JCO Precision Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.